Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon (BME: ORY) to sponsor Phelan-McDermid syndrome
Published by Arron Aatkar, PhD

Oryzon Genomics has announced that it will sponsor the first Phelan-McDermid syndrome (PMS) burden of illness study. The study, which was recently launched, and is being led by CureShank (a research advocacy organisation focused on expediting life-changing therapies for PMS), is collecting data from families of PMS patients, health insurance companies and taking insights from clinical experts. The ultimate aim is to quantify the economic impact of PMS, while informing the development of new treatment options, and guiding future market access strategies.

Oryzon’s lead CNS drug candidate vafidemstat has been designed to address agitation and aggression, which is a common feature of PMS. Since there are currently no approved pharmacological treatments for PMS, there could be a sizable opportunity for Oryzon in this space. The company plans to launch its Phase II HOPE-2 trial in PMS patients by end-2025, partially financed by funds received under the EU IPCEI MED4CURE grant.

Next Sparks Commentary in this sector >

Latest

TMT | Comment

Devolver Digital (LSE: DEVO): AIM cancellation proposed, with $5.0m tender offer attached

Industrials | Comment

Morgan Advanced Materials (LSE: MGAM) – Phasing lifts H126 margin

TMT | Comment

Pathos Communications (AIM: NEWS) – Record July revenue supports H126 trading update

Industrials | Comment

PVA TePla (FRA: PVE) – Q226 results

Industrials | Comment

Metlen Energy & Metals (LSE: MTLN; ATHEX: MYTIL) – Strong H1; FY26 and medium-term guidance confirmed
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.